Condition
Phase I
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Not Yet Recruiting1
Withdrawn1
Clinical Trials (2)
Showing 2 of 2 trials
NCT07818564Phase 1Not Yet RecruitingPrimary
Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation
NCT07428486Phase 1WithdrawnPrimary
A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
Showing all 2 trials